Azitra, Inc. (AZTR) company profile
Close on Nov 17, 2026Market cap $36.85MP/E –Yield –
About Azitra
Pharmaceutical Preparations, SIC 2834
Azitra, Inc. is an early-stage clinical biopharmaceutical company that develops innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The company focuses on genetically engineering commensal skin bacteria, primarily Staphylococcus epidermidis, to deliver therapeutic proteins and living organisms into deeper skin layers. Its product candidate pipeline includes ATR-12 for treating Netherton syndrome, ATR-04 for papulopustular rash caused by epidermal growth factor receptor inhibitor cancer therapies, and ATR-01 for ichthyosis vulgaris. Azitra serves patients suffering from rare, chronic, and treatment-induced dermatologic conditions.
The company operates a proprietary microbial library containing approximately 1,500 unique bacterial strains and over 60 distinct bacterial species. Azitra has not commenced commercial operations and pursues partnerships and licensing agreements with academic and research institutions across the United States. Azitra was incorporated under Delaware law, and the provided text does not disclose its specific headquarters location.
Summary of the business section of Azitra's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Azitra, Inc.
- Founded
- 2014
- Headquarters
- Branford, CT
- Address
- 21 Business Park Drive, Suite 6 06405
- Phone
- (203) 489-0183
- Website
- azitrainc.com
- Employees
- 13, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- GRASSI & CO., CPAs, P.C., Jericho, New York
Stock & identifiers
- Ticker
- AZTR
- Exchange
- NYSE
- IPO date
- Jun 21, 2023
- Shares outstanding
- 61M, Aug 11, 2026
- Public float
- $4.70M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-6.67 reverse, Aug 21, 2025; 1-for-6.67 reverse, Aug 21, 2025; 1-for-30 reverse, Jul 1, 2024
- SEC CIK
- 1701478
- CUSIP
- 05479L302
- ISIN
- US05479L3024
- FIGI
- BBG00GDC73T8
- Share class FIGI
- BBG00GDC73V5
- EIN
- 46-4478536
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Francisco D. Salva | President and CEO, Director | 4,086,291 |
| Travis Whitfill | Chief Operating Officer, Director | 334,500 |
| Norm Staskey | Chief Financial Officer | 51,100 |
| John R. Schroer | Director | – |
| Barbara Ryan | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Francisco Salva Pres. and CEO | $450.00K | $17.60K | $115.50K | $1.08K | $584.18K | +32% |
| Norman Staskey CFO | – | $3.84K | – | $493.64K | $497.48K | +9% |
| Travis Whitfill COO | $396.00K | $7.04K | $88.35K | $1.01K | $492.40K | +28% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jun 21, 2023
- Offer price
- $5.00
- Securities offered
- 1,500,000
- Gross proceeds
- $7.50M
- Exchange
- NYSE American
- First trading day
- Jun 20, 2023
- First-day close
- $4.47-10.7%
- Lock-up ends (est.)
- Dec 17, 2023
“The initial public offering price of our shares is $5.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of the date of this report, we have 13 employees and full-time consultants, including our executive officers, providing management and financial services, and general administrative responsibilities.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 13, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Dec 17, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 3, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jun 21, 2023 | IPO | Initial public offering priced (424B4 prospectus) |
| May 16, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?